Aby J. Mathew Sells 10,589 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 10,589 shares of BioLife Solutions stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $239,946.74. Following the sale, the executive vice president now directly owns 309,576 shares of the company’s stock, valued at $7,014,992.16. This represents a 3.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

BioLife Solutions Price Performance

Shares of BLFS stock opened at $20.88 on Friday. The business has a fifty day simple moving average of $25.87 and a 200 day simple moving average of $25.48. The company has a market cap of $981.36 million, a P/E ratio of -19.70 and a beta of 2.04. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a twelve month low of $14.84 and a twelve month high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the prior year, the business earned ($0.21) earnings per share. On average, sell-side analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of BioLife Solutions during the 4th quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions during the fourth quarter valued at about $31,000. 1620 Investment Advisors Inc. grew its holdings in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 675 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of BioLife Solutions by 27.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock valued at $117,000 after buying an additional 950 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in BioLife Solutions in the 4th quarter valued at approximately $171,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on BLFS. StockNews.com cut shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Monday, March 31st. KeyCorp increased their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Benchmark reiterated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, HC Wainwright raised their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.17.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.